EBV specific TCR redirected T cell therapy(Lion TCR)

N/A

Report date: 2022/02/14 16:09:48

Base Information

Drug NameEBV specific TCR redirected T cell therapy(Lion TCR)

Drug Alias NameEpstein Barr virus related nasopharyngeal carcinoma(Lion TCR)LT-C50

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity

TargetsNot applicable

Therapy Area/IndicationsNasopharyngeal Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySingapore

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesLion Tcr Pte Ltd

China Registration ClassN/A

Develop Information

Active CompaniesLion Tcr Pte Ltd

Inactive CompaniesN/A

Active IndicationsNasopharyngeal Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A